Brief: Ascletis Pharma Expects HY Loss Of RMB319.7 MLN
21/08/2026 16:45
BRIEF-Ascletis Pharma Expects HY Loss Of RMB319.7 MLN Aug 21 (Reuters) - Ascletis Pharma Inc 1672.HK:
EXPECTS LOSS OF RMB319.7 MILLION FOR H1 2026, UP 263.5% YOY
EXPECTED HY RESULT AS RESEARCH AND DEVELOPMENT EXPENSES INCREASED 132.7% TO RMB341.7 MILLION, OTHERS
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management